SEC Form 4 · accession 0001209191-18-051836

Principia Biopharma Inc. · PRNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Period of report

Sep 18, 2018

Accepted (ET)

Sep 20, 2018 · 6:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001510487

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Sep 18, 2018	C	1,070,771	—	A	1,070,771	I	See footnote
Common Stock^F1,F2,F3	Sep 18, 2018	C	312,741	—	A	1,383,512	I	See footnote
Common Stock^F1,F2,F3	Sep 18, 2018	C	260,617	—	A	1,644,129	I	See footnote
Common Stock^F1,F2,F3	Sep 18, 2018	C	544,047	—	A	2,188,176	I	See footnote
Common Stock^F1,F2,F3	Sep 18, 2018	C	167,537	—	A	2,355,713	I	See footnote
Common Stock^F2,F3	Sep 18, 2018	P	250,000	$17.00	A	2,605,713	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F1,F2,F3	—	Sep 18, 2018	C	1,070,771	D	—	—	Common Stock	1,070,771	0	I
Series B-1 Convertible Preferred Stock^F1,F2,F3	—	Sep 18, 2018	C	312,741	D	—	—	Common Stock	312,741	0	I
Series B-2 Convertible Preferred Stock^F1,F2,F3	—	Sep 18, 2018	C	260,617	D	—	—	Common Stock	260,617	0	I
Series B-3 Convertible Preferred Stock^F1,F2,F3	—	Sep 18, 2018	C	544,047	D	—	—	Common Stock	544,047	0	I
Series C Convertible Preferred Stock^F1,F2,F3	—	Sep 18, 2018	C	167,537	D	—	—	Common Stock	167,537	0	I
Warrant (Right to Buy)^{F2,F3,F4,F5,F1}	—	holding	—	—	—	—	Dec 29, 2022	Common Stock	28,623	28,623	I

F1All series of convertible preferred stock automatically converted into the number of shares of the Issuer's common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.
F2These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. By virtue of such relationships, GP IV and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI IV and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
F3This report on Form 4 is jointly filed by GP IV and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F4This warrant has converted from a warrant to purchase Series B-3 Preferred Stock into a warrant to purchase Common Stock.
F5This warrant is exercisable at any time.